Publication:
Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS

dc.contributor.authorKathy Leeen_US
dc.contributor.authorPornpun Vivithanapornen_US
dc.contributor.authorReed A. Siemieniuken_US
dc.contributor.authorHartmut B. Krentzen_US
dc.contributor.authorFerdinand Maingaten_US
dc.contributor.authorM. John Gillen_US
dc.contributor.authorChristopher Poweren_US
dc.contributor.otherAlberta Health Servicesen_US
dc.contributor.otherUniversity of Albertaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversity of Calgaryen_US
dc.date.accessioned2018-09-24T09:26:18Z
dc.date.available2018-09-24T09:26:18Z
dc.date.issued2010-06-17en_US
dc.description.abstractBackground: Anti-epileptic drugs (AEDs) are frequently prescribed to persons with HIV/AIDS receiving combination antiretroviral therapy (cART) although the extent of AED use and their interactions with cART are uncertain. Herein, AED usage, associated toxicities and immune consequences were investigated.Methods: HIV replication was analysed in proliferating human T cells during AED exposure. Patients receiving AEDs in a geographically-based HIV care program were assessed using clinical and laboratory variables in addition to assessing AED indication, type, and cumulative exposures.Results: Valproate suppressed proliferation in vitro of both HIV-infected and uninfected T cells (p <0.05) but AED exposures did not affect HIV production in vitro. Among 1345 HIV/AIDS persons in active care between 2001 and 2007, 169 individuals were exposed to AEDs for the following indications: peripheral neuropathy/neuropathic pain (60%), seizure/epilepsy (24%), mood disorder (13%) and movement disorder (2%). The most frequently prescribed AEDs were calcium channel blockers (gabapentin/pregabalin), followed by sodium channel blockers (phenytoin, carbamazepine, lamotrigine) and valproate. In a nested cohort of 55 AED-treated patients receiving cART and aviremic, chronic exposure to sodium and calcium channel blocking AEDs was associated with increased CD4+ T cell levels (p <0.05) with no change in CD8+ T cell levels over 12 months from the beginning of AED therapy.Conclusions: AEDs were prescribed for multiple indications without major adverse effects in this population but immune status in patients receiving sodium or calcium channel blocking drugs was improved. © 2010 Lee et al; licensee BioMed Central Ltd.en_US
dc.identifier.citationBMC Neurology. Vol.10, (2010)en_US
dc.identifier.doi10.1186/1471-2377-10-44en_US
dc.identifier.issn14712377en_US
dc.identifier.other2-s2.0-77953579619en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/29623
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77953579619&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleClinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDSen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77953579619&origin=inwarden_US
Files
Collections